Investigational drug · Phase 2
ADG126
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "ADG126"
First trial start
2020
Nov 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADG126", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced/Metastatic Solid Tumors
- Solid Tumor
- Advanced Liver Cancers
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ADG126" as an intervention, largest first.
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruiting
Incyte CorporationIncyte (INCY)
NCT05836324 · 570 participants (planned) · Start Jul 24, 2023 · Primary completion May 3, 2029
Drug: INCA33890; bevacizumab and 4 more · For: Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Los Angeles, California; Boston, Massachusetts; Grand Rapids, Michigan · 39 sites in all
SanofiSanofi (SNY)
NCT05584670 · 542 participants (planned) · Start Nov 29, 2022 · Primary completion Jan 19, 2027
Drug: SAR445877; Cetuximab and 4 more · For: Solid Tumor
Sites: Newark, Delaware; Iowa City, Iowa; Westwood, Kansas · 22 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04524871 · 518 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 30, 2027
Drug: Atezolizumab; Bevacizumab 15 mg/kg and 11 more · For: Advanced Liver Cancers
Sites: Costa Mesa, California; Duarte, California; Orange, California · 32 sites in all
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
Adagene IncIndustry
NCT05405595 · 186 participants (planned) · Start Jun 15, 2022 · Primary completion Jun 30, 2027
Drug: ADG126; Pembrolizumab (KEYTRUDA®) and 2 more · For: Advanced/Metastatic Solid Tumors
Sites: Scottsdale, Arizona; Duarte, California; Irvine, California · 21 sites in all
Adagene IncIndustry
NCT04645069 · 58 participants · Start Mar 15, 2021 · Primary completion Jan 29, 2024
Drug: ADG126 Mono; ADG126-anti PD1 and 1 more · For: Advanced/Metastatic Solid Tumors
Sites: Los Angeles, California; San Antonio, Texas; Miranda, Australia · 9 sites in all
City of Hope Medical CenterAcademic, hospital or other
NCT07363408 · 30 participants (planned) · Start Dec 1, 2026 · Primary completion Jul 21, 2027
Drug: Fluorouracil; Irinotecan and 3 more · For: Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8 and 1 more
Sites: Duarte, California
National University Hospital, SingaporeAcademic, hospital or other
NCT06846268 · 20 participants (planned) · Start Apr 14, 2025 · Primary completion Dec 31, 2027
Drug: ADG126; Pembrolizumab · For: Locally Advanced Colorectal Cancer
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced/Metastatic Solid Tumors
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- HRS-6719Phase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced/Metastatic Solid Tumors
- SYS6088Phase 21 trial
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.